

ORAL PRESENTATION

Open Access

Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets

Simon Bond^{1,2*}, Adrian Mander², John Todd³, Linda Wicker³, Frank Waldron-Lynch³

From 2nd Clinical Trials Methodology Conference: Methodology Matters
Edinburgh, UK. 18-19 November 2013

The objective of the DILT1D trial is to identify doses of interleukin-2 that achieve targeted increases in the T regulatory cell population in recently diagnosed type 1 diabetes. DILT1D aims to accurately identify a minimally effective dose and a maximal dose in a limited number of patients (40) that may be repeatedly administered in later phase trials.

The dose is administered subcutaneously so can be chosen from a continuous range up to a limit chosen on tolerability grounds. The design has an initial learning phase where pairs of patients are assigned to five pre-assigned doses. The next phase is fully sequential with an interim analysis after each patient to determine the choice of dose based on the optimality criterion to minimise the determinant of the covariance of the estimated target doses. The dose-choice algorithm assumes that a specific parametric dose-response model is the true relationship, and so a variety of models are considered at the interim and human judgement involved in the overall decision.

Simulation studies found that having two targets and assuming a model with a small number of parameters (≤ 3) leads to a choice of doses that are not near to the target doses. Fitting models with greater flexibility with more parameters (≥ 4) results in a choice of doses near to the target doses. Overall the design is efficient and seamlessly combines the initial learning and subsequent confirmatory stages.

Authors' details

¹Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. ²MRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge, UK. ³JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, Cambridge, UK.

¹Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Full list of author information is available at the end of the article

Published: 29 November 2013

doi:10.1186/1745-6215-14-S1-O78

Cite this article as: Bond et al.: Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets. *Trials* 2013 **14** (Suppl 1):O78.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

